| Literature DB >> 28418014 |
Zirong Huo1,2,3, Jun Shi1,2,3, Yilai Shu4,5, Mingliang Xiang1,2,3, Jingrong Lu1,2,3, Hao Wu2,3,6.
Abstract
Adenotonsillar regrowth in children after adenotonsillectomy (T&A) for obstructive sleep apnea (OSA) is often seen in clinical treatment, however, the relationship between allergic disease and adenotonsillar regrowth remains unclear. In this retrospective study, children were assigned to either the recurrence or control group, and subdivided by age at operation. Among children over 36 months, those in the recurrence group had more allergic disease and higher IgE, IL-4, and IL-5 levels than the same-aged children in control group. The Paediatric Allergic Disease Quality of Life Questionnaire (PADQLQ) scores for nasal symptoms and activity were higher in children older than 36 months in recurrence group. The results of immunohistochemistry and immunofluorescence showed that FoxP3+ cells (Tregs) were less, while GATA3+ cells (Th2 cells) were more in recurrence group for all ages. Allergic status and low levels of FoxP3 were proved as independent risk factors for adenotonsillar regrowth by multivariate logistic regression. These results indicate that allergic disease is a risk factor for adenotonsillar regrowth in children following T&A for OSA, and this risk increases with age. The decreased level of Tregs and subsequent changes in immune function play an important role in the pathogenesis of adenotonsillar regrowth.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28418014 PMCID: PMC5394537 DOI: 10.1038/srep46615
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Comparison of general data between recurrence and control group.
| Recurrence group N = 116 | Control group N = 178 | p value | |
|---|---|---|---|
| Gender | |||
| Male | 67 (57.8%) | 98 (55.1%) | NS |
| Female | 49 (42.2%) | 80 (44.9%) | |
| Age at operation (m) | 49.83 ± 22.23 (11–114) | 53.03 ± 26.08 (13–144) | NS |
| Duration of snoring and mouth breathing (m) | 14.07 ± 8.60 (2–48) | 13.71 ± 10.40 (2–60) | NS |
| MBI z-score before surgery | 0.76 ± 1.03 | 0.74 ± 1.08 | NS |
| Size of tonsil before operation | |||
| 3+ | 66 (56.9%) | 111 (62.4%) | NS |
| 4+ | 50 (43.1%) | 67 (37.6%) | |
| Preoperative PSG | |||
| AHI | 12.4 ± 2.8 | 12.0 ± 3.1 | NS |
| Lowest SaO2% | 85.6 ± 2.8 | 85.1 ± 2.8 | NS |
| Extracapsular tonsillectomy | 26 (26.7%) | 32 (28.1%) | NS |
Continuous variables are presented as mean ± SD, while categorical variables as frequency (percentage).
BMI: body mass index; PSG: polysomnography; AHI: apnea/hypopnea index; RDI: respiratory distress index.
Allergic status based on medical history, laboratory tests and PRQLQ results.
| Recurrence group N = 116 | Control group N = 178 | p value | |
|---|---|---|---|
| Medical history | |||
| AR | 48 (41.4%) | 40 (22.5%) | 0.001* |
| asthma | 16 (13.8%) | 11 (6.2%) | 0.045* |
| IgE (KU/L) | 94.29 ± 77.56 | 71.31 ± 41.60 | 0.004* |
| IFN-γ (pg/ml) | 50.60 ± 10.94 | 51.61 ± 9.50 | NS |
| IL-12 (pg/ml) | 35.96 ± 7.86 | 35.15 ± 7.33 | NS |
| IL-4 (pg/ml) | 63.03 ± 16.22 | 49.51 ± 13.06 | <0.001* |
| IL-5 (pg/ml) | 33.28 ± 8.81 | 28.63 ± 8.91 | <0.001* |
| PADQLQ | |||
| Nose symptoms | 16.64 ± 6.53 | 15.36 ± 5.37 | NS |
| “Other” symptomsa | 6.34 ± 2.85 | 6.06 ± 2.56 | NS |
| Emotions | 9.03 ± 3.31 | 8.50 ± 3.01 | NS |
| Everyday activities | 16.38 ± 10.94 | 10.96 ± 8.74 | NS |
Continuous variables are shown as mean ± SD, and categorical variables are shown as frequency (percentage).
IL: interleukin; IFN: interferon; PADQLQ; Paediatric Allergic Disease Quality of Life Questionnaire; AR: allergic rhinitis.
a “Other” symptoms include eyes, ears, lungs and skin symptoms16.
*p < 0.05.
Figure 1Localization of immunola belings of lymphocytes in adenotonsillar tissue.
CD45 was extensively expressed in the extrafollicular areas, tonsillar mantle zones, and germinal centers (a). CD3+ and CD4+ lymphocytes were localized primarily in the extrafollicular areas (b and c). The percentage of FoxP3+ lymphocytes, also located in the extrafollicular areas, was relatively low (d). Magnification ×40 HPF in the large map and ×400 HPF in the small map. Scaling bars indicate 200 μm for maps of 40 HPF and 20 μm for maps of 400 HPF.
Figure 2The number of CD45+, CD3+, CD4+, Gata3+ and FoxP3+ cells in the recurrence and control groups.
(a) Representative fluorescent staining of CD45, CD3, CD4, Gata3 and FoxP3 in the adenotonsillar tissues of control group and recurrence group (Magnification ×200 HPF). (b) There were no significant differences in the number of CD45+, CD3+ and CD4+ cells between the recurrence and control groups. (c) The number of Gata3+ cells was much higher (p < 0.001) in the recurrence group compared with the control group. (d) The number of FoxP3+ cells was significantly lower in the recurrence group compared with the control group (p < 0.001). *p < 0.05; ***p < 0.01.
Logistic regression analysis of possible risk factors for adenotonsillar regrowth.
| Variables | OR | Lower 95% confidence limit for OR | Upper 95% confidence limit for OR | p value |
|---|---|---|---|---|
| AHI | 0.928 | 0.845 | 1.019 | 0.118 |
| BMI z-score | 1.150 | 0.870 | 1.519 | 0.327 |
| Allergic disease | 2.953 | 1.614 | 5.401 | <0.001* |
| IgE | 0.988 | 0.982 | 0.993 | <0.001* |
| IL-4 | 0.937 | 0.918 | 0.956 | <0.001* |
| FoxP3 | 2.180 | 1.410 | 3.369 | <0.001* |
| GATA3 | 0.001 | <0.001 | 9.559 | 0.131 |
BMI: body mass index; IgE: immunoglobulin E; IL: interleukin; FoxP3: factor forkhead box P3; GATA3: GATA-binding protein 3; OR: odds ratio; CI: confidence interval.
*p < 0.05.